Ownership Summary
According to SEC filings for the period ending December 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) is held by 7 institutional firms.
- The collective stake of institutional investors in Apimeds Pharmaceuticals US moved to 3.1% in December 2025, a shift up from the 3.0% reported for September 2025.
- Institutional share ownership changed by 16.46% QoQ, while the number of institutional owners saw an unavailable change YoY.
- The latest 13F cycle for Apimeds Pharmaceuticals US reveals that of 7 total investors, 6 funds grew their exposure, whereas 0 reduced theirs and 1 made no changes.
- Collectively, institutional investors increased their stake in Apimeds Pharmaceuticals US to 395.70K shares as of December 2025, a change that is up by 55.92K shares quarter on quarter and down N/A shares year over year.
- Hemenway Trust Co LLC's holding of 274.00K shares as of December 31, 2025 makes it the primary institutional investor in Apimeds Pharmaceuticals US, owning 2.15% of the stock.
- Among the most significant buyers of Apimeds Pharmaceuticals US during December 2025 were JANE STREET GROUP, LLC (27.19K), Hemenway Trust Co LLC (24.00K), GEODE CAPITAL MANAGEMENT, LLC (4.13K), UBS Group AG (582), BANK OF AMERICA CORP /DE/ (11).
- The top 7 institutional holders of Apimeds Pharmaceuticals US for the quarter ending December 2025 included Hemenway Trust Co LLC (274.00K), VANGUARD GROUP INC (58.99K), GEODE CAPITAL MANAGEMENT, LLC (34.89K), JANE STREET GROUP, LLC (27.19K), UBS Group AG (582), BANK OF AMERICA CORP /DE/ (40), Tower Research Capital LLC (TRC) (10).